Gastrointestinal Toxicity With Celecoxib vs Nonsteroidal Anti-inflammatory Drugs for Osteoarthritis and Rheumatoid Arthritis: The CLASS Study: A Randomized Controlled Trial
Silverstein F, Faich G, Goldstein J, Simon L, Pincus T, Whelton A, Makuch R, Eisen G, Agrawal N, Stenson W, Burr A, Zhao W, Kent J, Lefkowith J, Verburg K, Geis G. Gastrointestinal Toxicity With Celecoxib vs Nonsteroidal Anti-inflammatory Drugs for Osteoarthritis and Rheumatoid Arthritis: The CLASS Study: A Randomized Controlled Trial. JAMA 2000, 284: 1247-1255. PMID: 10979111, DOI: 10.1001/jama.284.10.1247.Peer-Reviewed Original ResearchMeSH KeywordsAgedAnalysis of VarianceAnti-Inflammatory Agents, Non-SteroidalArthritis, RheumatoidAspirinCelecoxibCyclooxygenase 1Cyclooxygenase 2Cyclooxygenase 2 InhibitorsCyclooxygenase InhibitorsDiclofenacDouble-Blind MethodFemaleGastrointestinal DiseasesHumansIbuprofenIsoenzymesMaleMembrane ProteinsMiddle AgedOsteoarthritisPeptic UlcerProportional Hazards ModelsProspective StudiesProstaglandin-Endoperoxide SynthasesPyrazolesSulfonamidesConceptsNonsteroidal anti-inflammatory drugsConventional nonsteroidal anti-inflammatory drugsCelecoxib Long-term Arthritis Safety StudyCOX-2-specific inhibitorsUlcer complicationsSymptomatic ulcersAnti-inflammatory drugsRheumatoid arthritisIncidence rateAspirin useLower incidenceChronic GI blood lossToxic effectsAdverse effectsCelecoxib-treated patientsUpper GI toxicityUpper GI ulcersGI blood lossInhibition of cyclooxygenaseGI intoleranceCardiovascular eventsGastrointestinal toxicityGI toxicityImportant toxic effectsStudy drugUpper gastrointestinal tolerability of celecoxib, a COX-2 specific inhibitor, compared to naproxen and placebo.
Bensen W, Zhao S, Burke T, Zabinski R, Makuch R, Maurath C, Agrawal N, Geis G. Upper gastrointestinal tolerability of celecoxib, a COX-2 specific inhibitor, compared to naproxen and placebo. The Journal Of Rheumatology 2000, 27: 1876-83. PMID: 10955327.Peer-Reviewed Original ResearchMeSH KeywordsAbdominal PainAnti-Inflammatory Agents, Non-SteroidalArthritis, RheumatoidCelecoxibCyclooxygenase 2Cyclooxygenase 2 InhibitorsCyclooxygenase InhibitorsDigestive SystemDouble-Blind MethodDyspepsiaFemaleHumansIsoenzymesMaleMembrane ProteinsMiddle AgedNaproxenNauseaOsteoarthritisProspective StudiesProstaglandin-Endoperoxide SynthasesPyrazolesRisk FactorsSulfonamidesTime FactorsTreatment OutcomeConceptsUpper gastrointestinal tolerabilityUpper GI symptomsSevere abdominal painComposite endpointAbdominal painGastrointestinal tolerabilityGI symptomsIndependent predictorsRheumatoid arthritisRelative riskCOX-2-specific inhibitorsUpper GI tolerabilityTreatment group patientsDose-response relationshipGI tolerabilityPlacebo patientsGroup patientsCumulative incidenceParallel groupClinical trialsPlaceboPatientsCelecoxibTolerabilityEndpointOutcome of Children in the Indomethacin Intraventricular Hemorrhage Prevention Trial
Ment L, Vohr B, Allan W, Westerveld M, Sparrow S, Schneider K, Katz K, Duncan C, Makuch R. Outcome of Children in the Indomethacin Intraventricular Hemorrhage Prevention Trial. Pediatrics 2000, 105: 485-491. PMID: 10699097, DOI: 10.1542/peds.105.3.485.Peer-Reviewed Original ResearchMeSH KeywordsAnti-Inflammatory Agents, Non-SteroidalBrain Damage, ChronicCerebral HemorrhageCerebral VentriclesChild, PreschoolDose-Response Relationship, DrugFemaleFollow-Up StudiesHumansIndomethacinInfantInfant, NewbornInfant, Premature, DiseasesMaleNeurologic ExaminationNeuropsychological TestsPregnancyConceptsLow-dose indomethacinIntraventricular hemorrhagePlacebo childrenIndomethacin therapyPreterm infantsEarly administrationNeurologic examinationPrevention trialsLow birth weight preterm infantsStudy childrenBirth weight preterm infantsSeverity of IVHLow birth weight survivorsMean gestational ageWeight preterm infantsAdverse neurodevelopmental outcomesOutcome of childrenStandard neurologic examinationYears of ageNeurodevelopmental handicapPreterm neonatesNeurodevelopmental examinationNeurodevelopmental outcomesCerebral palsyGestational age